"The addition of a quadrivalent influenza vaccine gives healthcare providers a wider choice of vaccines that they can deliver without a needle," said Ron Lowy, PharmaJet Chairman and CEO. "PharmaJet offers the only needle-free delivery system approved by the FDA for administration of inactivated influenza vaccines. Expanding the vaccine selection that can be used with our device is another significant step toward improving public health through expanded immunization coverage, as well as improved safety of caregivers."
Refer to Instructions for Use to ensure safe injections and to review risks.
About PharmaJet
Based in Golden, Colorado, PharmaJet's mission is worldwide acceptance of PharmaJet needle-free devices as a standard of care in the vaccine delivery market. PharmaJet's devices are also integral in the development of multiple novel pharmaceuticals. The innovative Stratis® device has U.S. FDA 510(k) marketing clearance, CE Mark and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously. In August 2014, the PharmaJet Stratis® device was cleared for delivery of an influenza vaccine to deliver needle-free flu shots. The Tropis® device for intradermal injections received authorization to apply the CE Mark in May 2016. The PharmaJet Needle-free devices are safe, fast and easy-to-use. They eliminate needlestick injuries, needle reuse and cross contamination, and help reduce sharps waste disposal. For more information, visit www.pharmajet.com.
CONTACT:Nancy Lillie[email protected]
1-888-900-4321 Option 3
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/expanded-vaccine-offering-for-pharmajet-needle-free-device-300405281.html
SOURCE PharmaJet, Inc.
